Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial

Description

The Safe and Fast Radial Hemostasis using Synergistic Strategies (SAFE \& FAST) trial is an interventional study aimed at reducing the incidence of radial artery occlusion (RAO) rebound bleeding, and the required compression time after transradial approach (TRA) procedures, which have become the default access for coronary procedures globally. The hypothesis is that combining lower-dose heparin and radial hemostasis with simultaneous ipsilateral ulnar artery compression could achieve these improved outcomes.

Conditions

Cardiovascular Diseases, Bleeding, Arterial Puncture, Catheter Complications, Occlusion of Artery

Study Overview

Study Details

Study overview

The Safe and Fast Radial Hemostasis using Synergistic Strategies (SAFE \& FAST) trial is an interventional study aimed at reducing the incidence of radial artery occlusion (RAO) rebound bleeding, and the required compression time after transradial approach (TRA) procedures, which have become the default access for coronary procedures globally. The hypothesis is that combining lower-dose heparin and radial hemostasis with simultaneous ipsilateral ulnar artery compression could achieve these improved outcomes.

Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial

Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial

Condition
Cardiovascular Diseases
Intervention / Treatment

-

Contacts and Locations

Scranton

Regional Hospital of Scranton, Scranton, Pennsylvania, United States, 18510

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients referred for diagnostic transradial cardiac catheterization
  • 2. Age ≥ 18 years
  • 3. Ability to provide written informed consent
  • 1. Absence of written informed consent
  • 2. Patients on long-term systemic anticoagulation therapy for a different indication
  • 3. Patients requiring a heparin dose of greater than 50 units per kilogram before, during, or after the procedure for any reason.
  • 4. Patients requiring greater than 6 French catheter access

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Regional Hospital of Scranton,

Nishant Sethi, MD, PRINCIPAL_INVESTIGATOR, Regional Hospital of Scranton

Study Record Dates

2026-08-15